November 1, 2017 / 11:06 AM / 2 months ago

BRIEF-GSK and Innoviva announce positive data from COPD study

Nov 1 (Reuters) - Glaxosmithkline Plc

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

* GSK - ‍POSITIVE DATA FROM A STUDY COMPARING A ONCE-DAILY LAMA AND LABA FIXED-DOSE COMBINATION, ANORO ELLIPTA AND STIOLTO RESPIMAT FOR COPD​

* GSK - ‍ENDPOINT WAS MET, AND UMEC/VI DEMONSTRATED SUPERIORITY TO TIO/OLO, WITH A DIFFERENCE IN TREATMENT EFFECT OF 52ML ON TROUGH FEV1 AT WEEK EIGHT ​

* GLAXOSMITHKLINE PLC - ‍MOST FREQUENTLY-REPORTED ADVERSE EVENTS WERE UPPER RESPIRATORY TRACT INFECTIONS, COUGH AND DIARRHOEA​

* GLAXOSMITHKLINE PLC - ‍BOTH TREATMENTS DEMONSTRATED A COMPARABLE TOLERABILITY AND SAFETY PROFILE​

* GLAXOSMITHKLINE PLC - ‍OVERALL INCIDENCE OF ON-TREATMENT ADVERSE EVENTS OF 25% IN UMEC/VI GROUP AND 31% IN TIO/OLO GROUP​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below